Researchers hope that identifying the genomic alterations specific to transformed small cell lung cancer (SCLC) can help ...

The role of EGFR in KRASG12D-driven tumorigenesis was studied using mouse CRC organoids with KRAS-APC-TP53 mutations and ...

Patients with advanced non-small cell lung cancer and uncommon EGFR mutations lived almost twice as long without disease ...

Completed enrollment in global pivotal Phase 3 study for firmonertinib monotherapy in first-line NSCLC harboring EGFR exon 20 insertion mutationsPlanned update for development of firmonertinib in ...

C4 Therapeutics is sawing off another part of its solely owned pipeline, this time ending work on its clinical-stage BRAF ...

In the recent study, Ramalingam found that people with Stage III lung cancer who had EGFR mutations had an 84% lower risk of ...

After considering the feedback from consultation, the appraisal committee has prepared final draft guidance (FDG) on osimertinib with pemetrexed and platinum-based chemotherapy for untreated EGFR ...

Clinical data on track for Q4 2025 from Phase 2 trial of BDTX-1535 in 1L patients with non-classical EGFRm NSCLCExpansion of investigator sponsored Phase 0/1 trial into newly diagnosed glioblastoma ...